These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1633717)

  • 1. A chimaeric mouse model for autosomal-dominant polycystic kidney disease.
    Boulter CA; Aguzzi A; Evans MJ; Affara N
    Contrib Nephrol; 1992; 97():60-70. PubMed ID: 1633717
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study of the cyst forming mechanism by using pkd1-knockout chimera mice].
    Nishio K
    Hokkaido Igaku Zasshi; 2004 Nov; 79(6):695-703. PubMed ID: 15675299
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
    Wang X; Harris PC; Somlo S; Batlle D; Torres VE
    Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney and liver cysts in autosomal dominant polycystic kidney disease.
    Bichet DG
    Nephrol Dial Transplant; 2010 Nov; 25(11):3472-3. PubMed ID: 20846938
    [No Abstract]   [Full Text] [Related]  

  • 5. A model of polycystic kidney disease in SBM transgenic mice.
    Trudel M; D'Agati V
    Contrib Nephrol; 1992; 97():47-59. PubMed ID: 1321706
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell biology of human autosomal dominant polycystic kidney disease.
    Wilson PD
    Semin Nephrol; 1991 Nov; 11(6):607-16. PubMed ID: 1662822
    [No Abstract]   [Full Text] [Related]  

  • 7. Somatic mutation as mechanism for cyst formation in autosomal dominant polycystic kidney disease.
    Qian F; Watnick TJ
    Mol Genet Metab; 1999 Oct; 68(2):237-42. PubMed ID: 10527675
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease.
    Le NH; van der Wal A; van der Bent P; Lantinga-van Leeuwen IS; Breuning MH; van Dam H; de Heer E; Peters DJ
    J Am Soc Nephrol; 2005 Sep; 16(9):2724-31. PubMed ID: 16049073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vasculopathy of autosomal dominant polycystic kidney disease: insights from animal models.
    Arnaout MA
    Kidney Int; 2000 Dec; 58(6):2599-610. PubMed ID: 11115102
    [No Abstract]   [Full Text] [Related]  

  • 10. Imaging progression in polycystic kidney disease.
    Perrone R
    N Engl J Med; 2006 May; 354(20):2181-3. PubMed ID: 16707757
    [No Abstract]   [Full Text] [Related]  

  • 11. Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series.
    Poster D; Kistler AD; Krauer F; Blumenfeld JD; Rennert H; Weishaupt D; Wüthrich RP; Serra AL
    Am J Kidney Dis; 2009 Sep; 54(3):450-8. PubMed ID: 19515475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autosomal dominant polycystic disease: more than just empty space.
    Yee J
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):113-4. PubMed ID: 20219613
    [No Abstract]   [Full Text] [Related]  

  • 13. Autosomal dominant polycystic kidney disease.
    Ishikura K; Kamimaki I; Hamasaki Y; Hataya H; Ikeda M; Honda M
    Am J Kidney Dis; 2006 Jun; 47(6):A37, e73-5. PubMed ID: 16739257
    [No Abstract]   [Full Text] [Related]  

  • 14. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyst expansion and regression in a mouse model of polycystic kidney disease.
    Happé H; van der Wal AM; Salvatori DC; Leonhard WN; Breuning MH; de Heer E; Peters DJ
    Kidney Int; 2013 Jun; 83(6):1099-108. PubMed ID: 23466997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
    Zittema D; Versteeg IB; Gansevoort RT; van Goor H; de Heer E; Veraar KA; Peters DJ; Meijer E
    Am J Nephrol; 2016; 44(3):194-203. PubMed ID: 27578560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autosomal dominant polycystic kidney].
    Jorge Adad S; Estevão Barbosa M; Fácio Luíz JM; Furlan Rodrigues MC; Iwamoto S
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(1):18-20. PubMed ID: 8762650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of autosomal dominant polycystic kidney disease: recent developments.
    Grantham JJ
    Contrib Nephrol; 1997; 122():1-9. PubMed ID: 9399029
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic changes of breast in a family with autosomal dominant polycystic kidney disease.
    Maleki D; Ghafari A
    Iran J Kidney Dis; 2009 Oct; 3(4):246-8. PubMed ID: 19841531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic kidney disease in a Neva Masquerade cat.
    Jasik A; Kulesza M
    J Small Anim Pract; 2014 Jul; 55(7):387. PubMed ID: 24905486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.